Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Erdafitinib vs Vinflunine/Docetaxel/Pembrolizumab in Advanced Urothelial Cancer with FGFR Aberrations
jRCT2080223892Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2018
- Modality
- Small Molecules
01
Overview
Phase 3, randomised trial of erdafitinib in transitional cell carcinoma (TCC) (4 arms), sponsored by Janssen Pharmaceutical. Started May 2018; status: completed.
02
Drugs
erdafitinib
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on jRCT2080223892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223892.